Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$169.53
+1.0%
$175.34
$130.96
$182.89
$300.18B0.585.57 million shs510,613 shs
GSK plc stock logo
GSK
GSK
$40.92
+0.8%
$41.88
$33.33
$43.84
$84.80B0.643.45 million shs355,255 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$740.36
+1.2%
$763.83
$370.68
$800.78
$703.46B0.343.03 million shs338,778 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+0.92%+3.88%-5.89%+0.26%+3.40%
GSK plc stock logo
GSK
GSK
+2.14%+0.25%-4.13%+3.36%+10.60%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.69%-2.65%-5.10%+16.20%+89.83%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.903 of 5 stars
2.45.04.23.92.42.52.5
GSK plc stock logo
GSK
GSK
2.6882 of 5 stars
0.03.03.30.02.60.02.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8292 of 5 stars
2.44.02.54.02.42.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$177.435.65% Upside
GSK plc stock logo
GSK
GSK
2.40
HoldN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$728.05-0.45% Downside

Current Analyst Ratings

Latest ABBV, LLY, and GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
3/27/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$185.00 ➝ $195.00
3/22/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$188.00 ➝ $190.00
3/22/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$850.00
3/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$775.00 ➝ $850.00
3/4/2024
GSK plc stock logo
GSK
GSK
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
3/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$800.00 ➝ $1,000.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.47$15.96 per share10.52$5.78 per share29.06
GSK plc stock logo
GSK
GSK
$37.71B2.23$5.29 per share7.67$7.74 per share5.25
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.36$7.68 per share95.24$11.44 per share63.93

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$2.7361.5213.832.148.95%162.28%14.62%4/26/2024 (Confirmed)
GSK plc stock logo
GSK
GSK
$6.13B$3.0113.499.161.4016.24%51.45%10.57%5/1/2024 (Confirmed)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80126.0939.531.5815.36%51.22%9.94%4/30/2024 (Confirmed)

Latest ABBV, LLY, and GSK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
GSK plc stock logo
GSK
GSK
$0.95N/A-$0.95N/AN/AN/A
4/30/2024N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.61N/A-$2.61N/AN/AN/A  
4/26/2024N/A
AbbVie Inc. stock logo
ABBV
AbbVie
$2.20N/A-$2.20N/AN/AN/A  
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
2/2/202412/31/2023
AbbVie Inc. stock logo
ABBV
AbbVie
$2.76$2.79+$0.03$5.12$14.02 billion$14.30 billion    
1/31/2024Q4 2023
GSK plc stock logo
GSK
GSK
$0.76$0.72-$0.04$1.23$9.79 billion$10.00 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.69%+7.84%227.11%52 Years
GSK plc stock logo
GSK
GSK
$1.593.92%-18.20%52.82%1 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.71%+15.15%89.66%10 Years

Latest ABBV, LLY, and GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
2/1/2024
GSK plc stock logo
GSK
GSK
quarterly$0.35643.4%2/22/20242/23/20244/11/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
GSK plc stock logo
GSK
GSK
1.19
0.88
0.62
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
GSK plc stock logo
GSK
GSK
15.74%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
GSK plc stock logo
GSK
GSK
10.00%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
GSK plc stock logo
GSK
GSK
70,2002.07 billion1.87 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable

LLY, ABBV, and GSK Headlines

SourceHeadline
Olomorasib by Eli Lilly and Co for Ovarian Cancer: Likelihood of ApprovalOlomorasib by Eli Lilly and Co for Ovarian Cancer: Likelihood of Approval
pharmaceutical-technology.com - April 23 at 10:47 AM
Eli Lilly and Company (LLY) Rose due to Robust Q4 SalesEli Lilly and Company (LLY) Rose due to Robust Q4 Sales
finance.yahoo.com - April 23 at 10:47 AM
Eli Lilly and Company (NYSE:LLY) is Jennison Associates LLCs 5th Largest PositionEli Lilly and Company (NYSE:LLY) is Jennison Associates LLC's 5th Largest Position
marketbeat.com - April 23 at 8:29 AM
Hagens Berman Signals Major Turning Point in Insulin Fair Pricing Class-Action LawsuitHagens Berman Signals Major Turning Point in Insulin Fair Pricing Class-Action Lawsuit
businesswire.com - April 23 at 5:00 AM
Eli Lilly and Company (LLY) to Release Quarterly Earnings on TuesdayEli Lilly and Company (LLY) to Release Quarterly Earnings on Tuesday
americanbankingnews.com - April 23 at 2:36 AM
Eli Lilly and Company (NYSE:LLY) Holdings Reduced by Illinois Municipal Retirement FundEli Lilly and Company (NYSE:LLY) Holdings Reduced by Illinois Municipal Retirement Fund
marketbeat.com - April 22 at 9:59 PM
Eli Lilly (LLY) Advances But Underperforms Market: Key FactsEli Lilly (LLY) Advances But Underperforms Market: Key Facts
zacks.com - April 22 at 6:51 PM
Lilly to buy injectable drug plant in manufacturing ramp-upLilly to buy injectable drug plant in manufacturing ramp-up
biopharmadive.com - April 22 at 6:50 PM
Eli Lilly and Company (NYSE:LLY) Trading 0.2% Higher Eli Lilly and Company (NYSE:LLY) Trading 0.2% Higher
marketbeat.com - April 22 at 1:55 PM
Nexus Pharmaceuticals sells Pleasant Prairie facility to pharmaceutical giant Eli LillyNexus Pharmaceuticals sells Pleasant Prairie facility to pharmaceutical giant Eli Lilly
biztimes.com - April 22 at 1:50 PM
Eli Lilly buys injectable medicine manufacturing facility in WisconsinEli Lilly buys injectable medicine manufacturing facility in Wisconsin
msn.com - April 22 at 1:50 PM
7 High-Flying Stocks That Are Majorly Overdue for a Pullback7 High-Flying Stocks That Are Majorly Overdue for a Pullback
investorplace.com - April 22 at 1:43 PM
Eli Lilly to acquire manufacturing facility from Nexus PharmaEli Lilly to acquire manufacturing facility from Nexus Pharma
reuters.com - April 22 at 11:54 AM
Severity of sleep apnea comes down with Eli Lillys weight-loss drugSeverity of sleep apnea comes down with Eli Lilly's weight-loss drug
malaysiasun.com - April 22 at 8:49 AM
Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT) and Eli Lilly & Co (LLY)Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT) and Eli Lilly & Co (LLY)
markets.businessinsider.com - April 22 at 8:49 AM
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
marketbeat.com - April 22 at 6:05 AM
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (LLY)Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (LLY)
marketbeat.com - April 22 at 6:05 AM
Eli Lilly And The Alzheimers Dilemma (Rating Upgrade)Eli Lilly And The Alzheimer's Dilemma (Rating Upgrade)
seekingalpha.com - April 22 at 12:58 AM
Duality Advisers LP Acquires 2,253 Shares of Eli Lilly and Company (NYSE:LLY)Duality Advisers LP Acquires 2,253 Shares of Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 22 at 12:32 AM
11 Hot Growth Stocks To Buy Right Now11 Hot Growth Stocks To Buy Right Now
finance.yahoo.com - April 21 at 11:29 AM
Eli Lilly and Company (NYSE:LLY) Trading Down 2%Eli Lilly and Company (NYSE:LLY) Trading Down 2%
americanbankingnews.com - April 21 at 3:56 AM
Criterion Capital Advisors LLC Takes $1.34 Million Position in Eli Lilly and Company (NYSE:LLY)Criterion Capital Advisors LLC Takes $1.34 Million Position in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 20 at 5:00 PM
Eli Lilly’s Zepbound in shortage months after approvalEli Lilly’s Zepbound in shortage months after approval
msn.com - April 20 at 12:31 PM
Zepbound shortage: Weight loss drugs’ limited availability to continue, Eli Lilly saysZepbound shortage: Weight loss drugs’ limited availability to continue, Eli Lilly says
msn.com - April 20 at 12:31 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.